Lilya Shakirova handed two-year suspension from USADA

MMA news

Products You May Like

PhotoCred: Getty Images

UFC fans won’t be seeing Lilya Shakirova on their screens until 2022.

USADA announced on Monday that the UFC flyweight prospect had received a suspension for past usage of a banned substance.

“Shakirova, 29, tested positive for meldonium as the result of a sample collected out of competition on December 5, 2020 in her home country of Uzbekistan,” the statement read. “Meldonium is a non-Specified Substance in the category of Hormone and Metabolic Modulators and it is prohibited at all times under the UFC Anti-Doping Policy and the UFC Prohibited List.

“Upon being added to the UFC Anti-Doping Program, athletes are required to declare prohibited substances they have used in the previous 12 months. An athlete who makes such declaration will not be deemed to have committed a violation but, depending on the substance, may be required to refrain from competition for a period of at least six months and provide at least two negative samples. Shakirova did not declare the use of meldonium on her onboarding declaration forms.

“Shakirova’s two-year period of ineligibility began on December 5, 2020, the date her positive sample was collected.”

Uzbekistan’s Lilya Shakirova dropped to 8-2 in her professional career upon making her Octagon debut in October 2020. Stepping in to replace Cynthia Calvillo vs. Lauren Murphy at UFC 254, Shakirova suffered a second-round defeat via a rear-naked choke submission.

This article appeared first on BJPENN.COM

Products You May Like

Articles You May Like

UFC 325 Statement after CANCELLED bout, Alexander Volkanovski SHARES SCARY footage, Jon Jones REACTS
Muhammad Said Octagon Interview | UFC Abu Dhabi
UFC Superstar SPENDS $8 MILLION to move to him, Jon Jones and Khamzat Chimaev, Mackenzie Dern REACTS
UFC Belgrade press conference faceoffs: Uros Medic vs. Daniel Rodriguez
Jack Della Maddalena’s LAST MINUTE message, Jon Jones and Leon Edwards REACTS, UFC 322, Bo Nickal

Leave a Reply

Your email address will not be published. Required fields are marked *